[18F]AlF-NOTA-PCP2:一种新型PET/CT示踪剂用于增强胶质母细胞瘤异种移植模型中PD-L1异质性成像并与[18F]AlF-NOTA-WL12对比分析
本研究合成[18F]AlF-NOTA-PCP2并用表面等离子共振、细胞结合实验及胶质母细胞瘤异种移植模型评估其PD-L1亲和力、特异性和成像效果,并与[18F]AlF-NOTA-WL12对比。结果显示该示踪剂放射化学纯度>95%,亲和力与对照示踪剂相当,瘤血比更高、肝脏非特异性摄取更低、辐射暴露更少,能可视化PD-L1表达空间异质性。作者认为其临床转化尤其脑部成像需进一步临床试验验证。
要点
- [18F]AlF-NOTA-PCP2放射化学纯度>95%,对PD-L1亲和力与[18F]AlF-NOTA-WL12相当。
- 在胶质母细胞瘤异种移植模型中可可视化PD-L1表达水平及空间异质性。
- 较[18F]AlF-NOTA-WL12瘤血比更高、肝脏非特异性摄取更低、辐射暴露更少。
核心结论
- [18F]AlF-NOTA-PCP2是一种高灵敏度PET/CT示踪剂,可无创准确量化肿瘤尤其胶质母细胞瘤中PD-L1表达及其空间异质性。
- 其良好的药代动力学性质、安全性及对PD-L1的高亲和力提示有助提高癌症免疫治疗精准性并指导个体化治疗策略。
- 作者指出其临床转化尤其脑部成像需在临床试验中进一步验证。
研究设计与样本
- 研究合成[18F]AlF-NOTA-PCP2,用表面等离子共振和细胞结合实验表征其对PD-L1的亲和力。
- 体外用多种细胞系、体内用NOD/SCID小鼠胶质母细胞瘤异种移植模型评估PD-L1特异性。
- 进行PET/CT成像评估生物分布、药代动力学及量化肿瘤PD-L1表达空间异质性的能力,并与[18F]AlF-NOTA-WL12对比结合亲和力、生物分布、药代动力学和成像效果。
- 另通过人体辐射剂量学估算比较两种示踪剂的安全性。
主要发现
- [18F]AlF-NOTA-PCP2放射化学纯度>95%,对PD-L1亲和力强,与[18F]AlF-NOTA-WL12相当。
- 体外和体内研究证实其对PD-L1的特异性,在表达PD-L1的细胞和肿瘤中摄取增加。
- 毒理学分析显示血清生化指标或主要器官组织无明显异常。
- microPET/CT成像显示[18F]AlF-NOTA-PCP2可有效可视化胶质母细胞瘤异种移植模型中PD-L1表达水平及空间异质性。
- 对比研究显示[18F]AlF-NOTA-PCP2较[18F]AlF-NOTA-WL12具有更优药代动力学性质,包括更高的瘤血比和更低的肝脏非特异性摄取,以及更低的辐射暴露。
关键数值与推荐
- [18F]AlF-NOTA-PCP2放射化学纯度>95%。
- 体外和体内研究证实[18F]AlF-NOTA-PCP2对PD-L1具有特异性。
- 与[18F]AlF-NOTA-WL12相比,[18F]AlF-NOTA-PCP2瘤血比更高、肝脏非特异性摄取更低、辐射暴露更少。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 作者指出其临床转化尤其脑部成像需在临床试验中进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The unsatisfactory efficacy of PD-L1 antibodies in glioblastoma (GBM) is largely due to the temporal and spatial heterogeneity of PD-L1 expression. Molecular imaging can enhance understanding of the tumor immune microenvironment and guide immunotherapy. However, highly sensitive imaging agents capable of effectively visualizing PD-L1 heterogeneity are limited. This study introduces a novel PET tracer, offering improved imaging of PD-L1 heterogeneity in GBM xenografts, with a comparative analysis to [18F]AlF-NOTA-WL12. METHODS: [18F]AlF-NOTA-PCP2 was synthesized with high purity and its affinity for PD-L1 was characterized using surface plasmon resonance (SPR) and cell binding assays. Its specificity for PD-L1 was evaluated both in vitro using various cell lines and in vivo with GBM xenograft models in NOD/SCID mice. PET/CT imaging was conducted to evaluate the tracer's biodistribution, pharmacokinetics, and ability to quantify tumoral spatial heterogeneity of PD-L1 expression. A focused comparative analysis between [18F]AlF-NOTA-PCP2 and [18F]AlF-NOTA-WL12 was conducted, examining binding affinity, biodistribution, pharmacokinetics, and imaging effectiveness in GBM xenografts. Additionally, human radiation dosimetry estimates compared the safety profiles of both tracers. RESULTS: [18F]AlF-NOTA-PCP2 demonstrated high radiochemical purity (> 95%) and a strong affinity for PD-L1, comparable to [18F]AlF-NOTA-WL12. In vitro and in vivo studies confirmed its specificity for PD-L1, with increased uptake in PD-L1 expressing cells and tumors. Toxicological profiles indicated no significant abnormalities in serum biochemical indicators or major organ tissues. MicroPET/CT imaging showed [18F]AlF-NOTA-PCP2's effectiveness in visualizing PD-L1 expression levels and spatial heterogeneity in GBM xenografts. Comparative studies revealed [18F]AlF-NOTA-PCP2's improved pharmacokinetic properties, including higher tumor-to-blood ratios and lower nonspecific liver uptake, as well as reduced radiation exposure compared to [18F]AlF-NOTA-WL12. CONCLUSION: [18F]AlF-NOTA-PCP2 distinguishes itself as an exceptionally sensitive PET/CT tracer, adept at non-invasively and accurately quantifying PD-L1 expression and its spatial heterogeneity in tumors, especially in GBM. Its favorable pharmacokinetic properties, safety profile, and high affinity for PD-L1 highlight its potential for enhancing the precision of cancer immunotherapy and guiding individualized treatment strategies. While promising, its clinical translation, especially in brain imaging, necessitates further validation in clinical trials.
引用
- Wang Y, Zhang Y, Chen Y, et al. [18F]AlF-NOTA-PCP2: a novel PET/CT tracer for enhanced PD-L1 heterogeneity imaging and comparative analysis with [18F]AlF-NOTA-WL12 in glioblastoma xenografts. Eur J Nucl Med Mol Imaging. 2024. PMID: 38713298. doi:10.1007/s00259-024-06743-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。